James D Chalmers
Overview
Explore the profile of James D Chalmers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
437
Citations
10566
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
George J, Chalmers J, Coquelin K, Frame L, Henderson C, Kapelyukh Y, et al.
J Pharmacol Exp Ther
. 2025 Mar;
392(2):100053.
PMID: 40023599
The corticosteroid dexamethasone, which is used to treat numerous health conditions, remains the first-line treatment for patients hospitalized with COVID-19 requiring oxygen. Current British National Formulary prescribing advice warns of...
3.
Daynes E, Evans R, Greening N, Bishop N, Yates T, Lozano-Rojas D, et al.
Eur Respir J
. 2025 Feb;
PMID: 39978856
Objective: Post-COVID syndrome involves prolonged symptoms with multi-system and functional impairment lasting at least 12 weeks after acute COVID-19. We aimed to determine the efficacy of exercise-based rehabilitation interventions, either...
4.
Couillard S, Sykes D, Abdo M, Yang F, Ramakrishnan S, Chalmers J, et al.
Eur Respir J
. 2025 Feb;
PMID: 39947669
No abstract available.
5.
Johnson E, Long M, Perea L, Shih V, Fernandez C, Teper A, et al.
Am J Respir Crit Care Med
. 2025 Feb;
PMID: 39938076
Rationale: In the WILLOW trial, the Dipeptidyl peptidase-1 inhibitor brensocatib reduced neutrophil serine protease (NSP) activity and prolonged time to first exacerbation in patients with bronchiectasis. Objectives: We hypothesized that,...
6.
7.
Williams D, Hawkins A, Hernandez R, Mariano G, Mathers K, Buchanan G, et al.
Cell Host Microbe
. 2025 Jan;
33(2):252-266.e5.
PMID: 39884275
Opportunistic bacterial pathogens must compete with other bacteria and switch between host- and environment-adapted states. Type VI secretion systems (T6SSs) occur widely in gram-negative bacteria and can efficiently kill neighboring...
8.
Chalmers J, Loebinger M, Teper A, McShane P, Fernandez C, Fucile S, et al.
ERJ Open Res
. 2025 Jan;
11(1.
PMID: 39872387
Introduction: Bronchiectasis is a chronic inflammatory airway disease. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), reduces pulmonary inflammation by preventing the activation of neutrophil serine proteases. In...
9.
Nguyen-Ho L, Trinh H, Le-Thuong V, Le K, Vo V, Vu D, et al.
Tuberc Respir Dis (Seoul)
. 2025 Jan;
PMID: 39806808
Background: Neutrophil elastase (NE) has been proposed as a potential biomarker for evaluating the severity and prognosis of bronchiectasis. This study aimed to compare bronchial lavage quantification of NE levels...
10.
Xu J, Zheng H, Lu H, Wang L, Wu B, Lv X, et al.
Lancet Respir Med
. 2025 Jan;
13(2):166-176.
PMID: 39805296
Background: Bronchiectasis is a disease with a global impact, but most published data come from high-income countries. We aimed to describe the clinical characteristics of patients with bronchiectasis in China....